Skip to main content

Primary biliary cirrhosis immunopathogenesis and optimum management

Publication ,  Journal Article
Lilly, L; Berg, CL; Gollan, JL
Published in: Clinical Immunotherapeutics
January 1, 1996

Primary biliary cirrhosis is a well-characterised disorder of autoimmune origin whose exact pathogenesis remains poorly understood. Population studies have suggested an association with human leucocyte antigen (HLA)-DRS, and patients are universally positive for antimitochondrial antibodies; however, the clinical relevance of these observations is unclear. Other putative autoantigens have been proposed. Numerous abnormalities throughout the immune system as well as in complement pathways have been characterised, and major histocompatibility complex (MHC) expression on biliary epithelial cells is increased. Consequently, drugs whose actions are primarily immunomodulatory have undergone testing in the therapy of primary biliary cirrhosis, but none have demonstrated particular promise. Ursodeoxycholic acid remains the therapy of choice, and it is believed to exert its beneficial effects by modifying bile salt pool content and kinetics, as well as possibly through immunological mechanisms. Improvement in biochemical and clinical parameters with ursodeoxycholic acid therapy is well recognised, and it also appears to improve hepatic histology and retard progression to transplantation or death. Antifibrotic therapy with colchicine has shown some promise in small studies; however, the results of larger clinical trials designed to examine its role in conjunction with ursodeoxycholic acid are not yet available. Liver transplantation is the established treatment for end-stage primary biliary cirrhosis, and recurrent disease in the allograft has not been satisfactorily documented. t> Adis international Limited Ali rights reserved.

Duke Scholars

Published In

Clinical Immunotherapeutics

DOI

ISSN

1172-7039

Publication Date

January 1, 1996

Volume

5

Issue

6

Start / End Page

420 / 437

Related Subject Headings

  • Immunology
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lilly, L., Berg, C. L., & Gollan, J. L. (1996). Primary biliary cirrhosis immunopathogenesis and optimum management. Clinical Immunotherapeutics, 5(6), 420–437. https://doi.org/10.1007/BF03259338
Lilly, L., C. L. Berg, and J. L. Gollan. “Primary biliary cirrhosis immunopathogenesis and optimum management.” Clinical Immunotherapeutics 5, no. 6 (January 1, 1996): 420–37. https://doi.org/10.1007/BF03259338.
Lilly L, Berg CL, Gollan JL. Primary biliary cirrhosis immunopathogenesis and optimum management. Clinical Immunotherapeutics. 1996 Jan 1;5(6):420–37.
Lilly, L., et al. “Primary biliary cirrhosis immunopathogenesis and optimum management.” Clinical Immunotherapeutics, vol. 5, no. 6, Jan. 1996, pp. 420–37. Scopus, doi:10.1007/BF03259338.
Lilly L, Berg CL, Gollan JL. Primary biliary cirrhosis immunopathogenesis and optimum management. Clinical Immunotherapeutics. 1996 Jan 1;5(6):420–437.

Published In

Clinical Immunotherapeutics

DOI

ISSN

1172-7039

Publication Date

January 1, 1996

Volume

5

Issue

6

Start / End Page

420 / 437

Related Subject Headings

  • Immunology
  • 1115 Pharmacology and Pharmaceutical Sciences